MY APPROACH to the patient with arrhythmogenic right ventricular cardiomyopathy (ARVC). by Asimaki, A
Clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC) is challenging owing to 
the broad range of phenotypic manifestations, reduced genetic penetrance and age-related progression 
characterizing the disease. There is no single “gold-standard” test for ARVC and diagnosis relies on a 
scoring system of “major” and “minor” criteria based on the demonstration of a combination of defects 
in ventricular morphology and function, depolarization/repolarization ECG abnormalities, myocardial 
tissue histological changes, arrhythmias and family history. Definitive diagnosis, based on the Revised 
2010 Task Force Criteria (TFC), requires 2 major, 1 major and 2 minor or 4 minor criteria from different 
categories. Therefore, the initial evaluation of all patients suspected of having ARVC should include 
physical examination, clinical history, family history of arrhythmias or sudden cardiac death (SCD), 
ECG, signal-averaged ECG, Holter monitoring and non-invasive imaging tests, typically 
echocardiography. Following the recent identification of left-dominant and biventricular forms of ARVC, 
comprehensive imaging of the LV is also indicated.  
More recently, cardiac magnetic resonance (CMR) has been introduced in the clinical practice when 
evaluating a patient with possible ARVC as it can quantitatively assess ventricular volumes and ejection 
fractions, wall motion abnormalities, and give information on tissue characterization (fatty infiltration and 
myocardial fibrosis through late gadolinium enhancement). If a non-invasive workup is suggestive but 
not diagnostic, further testing should be considered including angiography, electroanatomic mapping 
and rarely endomyocardial biopsy.  
The most important task when managing a patient with ARVC is prevention of SCD. Patients with a 
history of aborted SCD or sustained VT are considered high-risk and should get an ICD. Syncope, non-
sustained VT, family history of SCD, severe RV dysfunction, LV involvement and QRS dispersion are 
considered intermediate risk factors but their individual or combined prognostic value has not been 
prospectively assessed. Accordingly, ICD implantation should be decided in a case-by-case basis. 
Radiofrequency ablation should be considered in those patients who are not candidates for an ICD or 
who have an ICD but get multiple shocks despite pharmacological treatment.  
Anti-arrhythmic medications may be used to control symptoms in ARVC. The combination of beta-
blockers (sotalol) and amiodarone has been proved beneficial in reducing sustained VT and preventing 
syncope. Beta-blockers and ACE inhibitors can also be used in ARVC patients particularly those with 
biventricular dysfunction or heart failure. Cardiac transplantation is indicated in patients with severe 
heart failure (typically characterizing end-stage disease) and in selected cases with intractable, 
incessant ventricular arrhythmias.  
Particular caution should be addressed to avoid competitive sport activities, which increase disease 
progression and arrhythmic risk. ARVC is familial in >50% of cases. Screening of family members is 
therefore of pivotal importance. Clinical evaluation of relatives should be guided by the observation that 
SCD in ARVC is extremely rare at <10 years of age. Family members who meet TFC should be closely 
monitored. However, since electrical abnormalities precede structural changes in ARVC, evaluation in 
family members not meeting TFC should initially focus on the electrical aspects of the disease by ECG 
and Holter monitoring. Alternatively, genetic testing can be performed and if a pathogenic mutation is 
identified in the proband, family members can be tested as well to determine whether they are at risk of 
disease manifestation in the future.  
